Biotech Co.* (Country; Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date) FIRST QUARTER Access Pharmaceuticals Inc. (AMEX:AKC) RHEI Pharmaceuticals Inc. Agreement to market MuGard in China and certain other Southeast Asian countries RHEI will be responsible for marketing the product in China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam, and will handle manufacturing and regulatory

I. MODIFIED AGREEMENTS Biotech Co.* (Country; Symbol) Pharma Co. (Country) Change from original agreement Terms/Details (Date) FIRST QUARTER Affymetrix Inc. (AFFX) NimbleGen Systems Inc. (subsidiary of F. Hoffmann-La Roche Ltd.; Switzerland) Expanded license for a number of patents originally granted in October 2006 The expanded license provides certain diagnostic rights for array-based DNA copy number analysis and array-based resequencing, in addition to covering the manufacture, use and

I. MODIFIED AGREEMENTS Company* (Country; Symbol) Company* (Country; Symbol) Product Terms/Details (Date) FIRST QUARTER ABR-Affinity BioReagents Inc.* Osenses Pty. Ltd.* Reverse distribution agreement to distribute Osenses products in the U.S., Europe and Canada Osenses offers primary antibodies for experimental use in the areas of chemo-sensory, visual, auditory and transient receptors (3/3) Alfacell Corp. (Canada; ACEL) Scientific Protein Laboratories LLC* Purchase and supply agreement

I. MODIFIED AGREEMENTS Company* (Country; Symbol) Company* (Country; Symbol) Change from original agreement Terms/Details (Date) FIRST QUARTER Alimera Sciences Inc.* pSivida Ltd. (PSDV) Amended license and collaboration agreement relating to Medidur FA for diabetic macular edema, and other Medidur products Alimera is increasing its equity in the future profits of Medidur FA from 50% to 80%, in exchange for consideration of up to about $78M to pSivida, including $12M up front (3/17

Biotech Co.* (Country; Symbol) Agbiotech Partner (Country; Symbol) Type/Product Area Terms/Details (Date) I. BIO/AG AGREEMENTS Algenol Biofuels* Condon Devices* Multiyear partnership to use Condon's BioLOGIC protein engineering platform in developing environmentally friendly biofuels, such as ethanol Financial terms were not disclosed (7/8) Amarillo Biosciences Inc. (OTC BB: AMAR) CytoPharm Inc.* (Taiwan) License and supply agreement to conduct animal (swine, poultry and cattle) clinical

Company* (Symbol) University/Non-Profit Type Of Agreement Product Area Details (Date) FIRST QUARTER Acacia Research The Centre for Partnership To gain access to the Acacia's division CombiMatrix Corp. (ACTG) Applied Genomics consortium's published Molecular Diagnostics plans to (Canada) markers for autism use them in upcoming versions of its Constitutional Genetic Array Test (3/7) Advanced Cell Casey Eye Sponsored To conduct preclinical The research team is conduc

Company* (Country; Symbol) Company* (Country; Symbol Type/Product Area Terms/Details (Date) FIRST QUARTER Accentia Bio- Revimmune Accentia acquired ex- Accentia is preparing an investigational Pharmaceuticals LLC* clusive worldwide rights new drug application for severe refractory Inc. (ABPI) to autoimmune disease multiple sclerosis and is proposing a drug Revimmune Phase III program (2/28) Advanced Cell Infigen Inc.* Agreement for intellectual A total of 26 issued patents and a

Biotech Co. (Country; Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date) FIRST QUARTER Abeille SymBio SymBio got rights to develop Abeille gets an up-front licensing fee and Pharmaceuticals Pharmaceuticals and sell AB-1001 in Japan, potential milestone payments of up to Inc.* Ltd. (Japan) China, Korea, Taiwan and $21M; it also would get double-digit royal- Singapore; AB-1001 is a ties; SymBio also got a right of first refusal transdermal patch for on Abeille's next

Company* (Symbol)** Funding Institution Amount (M) Type Details (Date) FIRST QUARTER Addrenex The North Carolina $0.15 Research loan Loan will support the develop- Pharmaceuticals* Biotechnology ment of Clonicel, an oral, ex- Center tended-release formulation for symptoms associated with ex- cessive adrenaline secretion (1/8) Advanced Cell National Institutes $0.204 Research grant The grant will fund the compa- Technology Inc. of Health ny's embryonic stem cell

Total: $1,151.37M Company (Symbol)# Partner (Country) Amt. (M) Triggering Event Details (Date) JANUARY Acumen Merck & Co. Inc. $5 Milestone Acumen received the payment in relation to Pharmaceuticals payment its 2003 license agreement to research and Inc.* develop disease-modifying therapies for Alzheimer's disease and other memory- related disorders (1/22) BioCryst Mundipharma $5 Milestone Triggered by the start of a pivotal trial of Pharmaceuticals International

Company Acquired (Country; Symbol) Acquired By Or Merged With (Country; Symbol) Date Announced Date Completed Value (M) Terms/Details (Date) I. COMPLETED MERGERS AND ACQUISITIONS FIRST QUARTER Acuity Pharmaceuticals Inc. and Froptix Corp. eXegenics Inc. (OTC BB:EXEG) 3/27/07 3/27/07 N/A Companies merged with eXegenics, a public shell, giving them access to $16M in cash; new company will be called Opko Corp. and will be based in Miami AdviSys Inc.VGX Pharmaceuticals Inc.2/26/07 2/26/07 ND

Company* (Country; Symbol) Company* (Country; Symbol) Type/Product Area Terms/Details (Date) FIRST QUARTER CV Therapeutics Inc. (CVTX) Medlogics Device Corp.* Licensing agreement for CV's biopolymer stent-coating technology to develop a drug eluting stent Financial terms were not disclosed, but CV received Medlogics' stock and is entitled to development milestone payments, royalties and other potential payments on future sales of any product incorporating the technology (2/5) Forticell

Company* Product Marketer Indication (U.S. Approval Month/Year) Abbott Laboratories Humira Abbott Laboratories Moderately to severely active Crohn's disease (2/07) Abraxis BioScience Inc. Oxytocin Abraxis BioScience To initiate or improve uterine contractions in labor-related issues (8/07) Acambis plc ACAM2000 Acambis plc Smallpox (9/07) Access Pharmaceuticals Inc. MuGard Access Pharmaceuticals Oral mucositis in cancer patients (12/06) Acorda Therapeutics Inc. Zanaflex Acorda

Company* (Symbol) Product Description Indication Action/Date ActivBiotics* M40403 A small molecule that mimics the action of a natural component of the cells, an enzyme called superoxide dismutase To prevent oral mucositis in head and neck cancer patients CMPH granted orphan drug designation (2/5); received orphan drug designation from the FDA (3/6) Adherex Technologies Inc. (AMEX:ADH) ADH-1 Cadherin antagonist; small peptide, tumor/vascular-targeting agent Malignant melanoma Received

Company* (Symbol) Product Description Indication Action/Date 3SBio Inc. NuLeusin A second-generation interleukin-2 agent; genetically modified to improve biochemical properties over naturally occurring IL-2 Metastatic renal-cell carcinoma Filed for approval in China (SSRX) (11/10) Abraxis BioScience Inc. (ABII) Abraxane Powder for suspension for infusion (an albumin-bound nanoparticle formulation of paclitaxel Metastatic breast cancer European Commission granted marketing approval (1

Company* (Symbol) Product Description Indication Action/Date Acusphere Inc. (ACUS) Imagify Perflubutane polymer microspheres for injectable suspension To detect coronary artery disease Submitted an NDA (4/29); FDA accepted it for review (6/30) Advanced Life Sciences Holdings Inc. (ADLS) Cethromycin Antibiotic Community-acquired pneumonia Submitted an NDA (10/1); FDA accepted it for filing (12/3) Advaxis Inc. (OTC BB:ADXS) Lovaxin C A live Listeria vaccine; a bioengineered microbe Cervical

Company* (Symbol) Product Description Indication Action/Date Acusphere Inc. (ACUS) Imagify Perflubutane polymer microspheres To detect coronary artery disease FDA raised safety concerns of vasovagal syncope, cyanosis, hypotension and rigors (12/8); FDA advisory panel voted 16-1 against it, saying efficacy data is not sufficient to justify its risk (12/11) Adolor Corp. (ADLR) Entereg Alvimopan Postoperative ileus FDA committee recommended approval (1/23) Amgen Inc. (AMGN) Romiplostim

Company* (Symbol) Product Description Indication Action/Date AMAG Pharmaceuticals Inc. (AMAG) Ferumoxytol Intravenous treatment Iron deficiency anemia associated with chronic kidney disease FDA accepted for review the NDA (2/19); received a complete response letter from the FDA (10/20); FDA decided to review the company's resubmitted information (11/13) Basilea Pharmaceutical AG (Switzerland; SWX:BSLN) Ceftobiprole An anti-MRSA broad-spectrum cephalosporin Complicated skin and skin

Company* (Symbol) Product Description Indication Action/Date Abbott (NYSE:ABT) Humira Adalimumab Moderately to severely active polyarticular juvenile idiopathic arthritis FDA approved Humira for the new indication in patients four years or older (2/22) Abbott (NYSE:ABT) Simcor A fixed-dose combination of Niaspan, the firm's extended-release form of niacin, and simvastatin Complex lipid disease FDA approved Simcor to lower levels of elevated low-density lipoprotein cholesterol and